News & Views: Porterhouse Insights

The MHRA published its 2030 Strategy on 14 October 2026. It sets out how UK regulation of medicines, devices and AI will change over the next five years, with patient safety, faster access and scientific excellence at its centre.  Much of the coverage has focused on timelines and AI. For insight and evidence teams, the …

Continue reading “MHRA Strategy 2030: what it means for insight and evidence”

A phase two readout lands. Weeks later, in your first regulatory meeting, you discover the new joint clinical assessment process requires comparator data you don’t have. The trial has already finished enrolling. There’s no going back to fix the design.  It’s the scenario that opens episode one of The Value Equation, our new podcast on …

Continue reading “Introducing The Value Equation: a new podcast from SCIRIS Group”